Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018). Targeting the tumour stroma to improve cancer therapy. Nature Reviews. Clinical Oncology, 15(6), 366–381. https://doi.org/10.1038/s41571-018-0007-1
Article PubMed PubMed Central Google Scholar
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020). Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nature Reviews. Gastroenterology & Hepatology, 17(8), 487–505. https://doi.org/10.1038/s41575-020-0300-1
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016). Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nature Reviews Clinical Oncology, 13(12), 750–765. https://doi.org/10.1038/nrclinonc.2016.119
CAS Article PubMed Google Scholar
Maeda, H. (2015). Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Advanced Drug Delivery Reviews, 91, 3–6. https://doi.org/10.1016/j.addr.2015.01.002
CAS Article PubMed Google Scholar
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., & Tuveson, D. A. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, N.Y.), 324(5933), 1457–1461. https://doi.org/10.1126/science.1171362
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., & Kindler, H. L. (2015). Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33(36), 4284–4292. https://doi.org/10.1200/JCO.2015.62.8719
De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., & Laheru, D. A. (2020). Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122(4), 498–505. https://doi.org/10.1038/s41416-019-0683-3
CAS Article PubMed Google Scholar
Kim, E. J., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N., & Simeone, D. M. (2014). Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20(23), 5937–5945. https://doi.org/10.1158/1078-0432.CCR-14-1269
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., & Beachy, P. A. (2014). Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 111(30), E3091-3100. https://doi.org/10.1073/pnas.1411679111
CAS Article PubMed PubMed Central Google Scholar
Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., & Hendifar, A. E. (2018). HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(4), 359–366. https://doi.org/10.1200/JCO.2017.74.9564
Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., HALO 109-301 Investigators. (2020). Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38(27), 3185–3194. https://doi.org/10.1200/JCO.20.00590
Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., & Hochster, H. S. (2019). Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(13), 1062–1069. https://doi.org/10.1200/JCO.18.01295
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006). Photodynamic therapy and anti-tumour immunity. Nature Reviews Cancer, 6(7), 535–545. https://doi.org/10.1038/nrc1894
CAS Article PubMed PubMed Central Google Scholar
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003). Photodynamic therapy for cancer. Nature Reviews. Cancer, 3(5), 380–387. https://doi.org/10.1038/nrc1071
CAS Article PubMed Google Scholar
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., & Hasan, T. (2010). Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chemical Reviews, 110(5), 2795–2838. https://doi.org/10.1021/cr900300p
CAS Article PubMed PubMed Central Google Scholar
Araki, T., Ogawara, K., Suzuki, H., Kawai, R., Watanabe, T., Ono, T., & Higaki, K. (2015). Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature. Journal of Controlled Release: Official Journal of the Controlled Release Society, 200, 106–114. https://doi.org/10.1016/j.jconrel.2014.12.038
Luo, D., Carter, K. A., Razi, A., Geng, J., Shao, S., Giraldo, D., & Lovell, J. F. (2016). Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials, 75, 193–202. https://doi.org/10.1016/j.biomaterials.2015.10.027
CAS Article PubMed Google Scholar
Luo, D., Carter, K. A., Molins, E. A. G., Straubinger, N. L., Geng, J., Shao, S., & Lovell, J. F. (2019). Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. Journal of Controlled Release: Official Journal of the Controlled Release Society, 297, 39–47. https://doi.org/10.1016/j.jconrel.2019.01.030
Huang, H.-C., Rizvi, I., Liu, J., Anbil, S., Kalra, A., Lee, H., & Hasan, T. (2018). Photodynamic priming mitigates chemotherapeutic selection pressures and improves drug delivery. Cancer Research, 78(2), 558–571. https://doi.org/10.1158/0008-5472.CAN-17-1700
CAS Article PubMed Google Scholar
Luo, D., Carter, K. A., Geng, J., He, X., & Lovell, J. F. (2018). Short drug-light intervals improve liposomal chemophototherapy in mice bearing MIA PaCa-2 xenografts. Molecular Pharmaceutics, 15(9), 3682–3689. https://doi.org/10.1021/acs.molpharmaceut.8b00052
CAS Article PubMed Google Scholar
Sorrin, A. J., Kemal Ruhi, M., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., & Rizvi, I. (2020). Photodynamic therapy and the biophysics of the tumor microenvironment. Photochemistry and Photobiology, 96(2), 232–259. https://doi.org/10.1111/php.13209
CAS Article PubMed PubMed Central Google Scholar
Obaid, G., Bano, S., Mallidi, S., Broekgaarden, M., Kuriakose, J., Silber, Z., & Hasan, T. (2019). Impacting pancreatic cancer therapy in heterotypic in vitro organoids and in vivo tumors with specificity-tuned, NIR-activable photoimmunonanoconjugates: Towards conquering desmoplasia? Nano letters, 19(11), 7573–7587. https://doi.org/10.1021/acs.nanolett.9b00859
CAS Article PubMed PubMed Central Google Scholar
Düzgüneş, N., Piskorz, J., Skupin-Mrugalska, P., Goslinski, T., Mielcarek, J., & Konopka, K. (2018). Photodynamic therapy of cancer with liposomal photosensitizers. Therapeutic Delivery, 9(11), 823–832. https://doi.org/10.4155/tde-2018-0050
CAS Article PubMed Google Scholar
Broekgaarden, M., Weijer, R., van Gulik, T. M., Hamblin, M. R., & Heger, M. (2015). Tumor cell survival pathways activated by photodynamic therapy: A molecular basis for pharmacological inhibition strategies. Cancer Metastasis Reviews, 34(4), 643–690. https://doi.org/10.1007/s10555-015-9588-7
CAS Article PubMed PubMed Central Google Scholar
Kushibiki, T., Hirasawa, T., Okawa, S., & Ishihara, M. (2013). Responses of cancer cells induced by photodynamic therapy. Journal of Healthcare Engineering, 4(1), 87–108. https://doi.org/10.1260/2040-2295.4.1.87
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020). Clinical development and potential of photothermal and photodynamic therapies for cancer. Nature Reviews. Clinical Oncology, 17(11), 657–674. https://doi.org/10.1038/s41571-020-0410-2
Willenbrink, T. J., Ruiz, E. S., Cornejo, C. M., Schmults, C. D., Arron, S. T., & Jambusaria-Pahlajani, A. (2020). Field cancerization: Definition, epidemiology, risk factors, and outcomes. Journal of the American Academy of Dermatology, 83(3), 709–717. https://doi.org/10.1016/j.jaad.2020.03.126
CAS Article PubMed Google Scholar
Jansen, M. H. E., Kessels, J. P. H. M., Nelemans, P. J., Kouloubis, N., Arits, A. H. M. M., van Pelt, H. P. A., & Mosterd, K. (2019). Randomized trial of four treatment approaches for actinic keratosis. The New England Journal of Medicine, 380(10), 935–946. https://doi.org/10.1056/NEJMoa1811850
CAS Article PubMed Google Scholar
Wollina, U., Gaber, B., & Koch, A. (2018). Photodynamic treatment with nanoemulsified 5-aminolevulinic acid and narrow band red light for field cancerization due to occupational exposure to ultraviolet light irradiation. Georgian Medical News, 274, 138–143.
Haque, T., Rahman, K. M., Thurston, D. E., Hadgraft, J., & Lane, M. E. (2015). Topical therapies for skin cancer and actinic keratosis. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 77, 279–289. https://doi.org/10.1016/j.ejps.2015.06.013
Stewart, T. J., Farrell, J., Crainic, O., & Rosen, R. H. (2020). A large series of pigmented Bowen’s disease. International Journal of Dermatology, 59(9), e316–e317. https://doi.org/10.1111/ijd.14977
de Faria, C. M. G., Barrera-Patiño, C. P., Santana, J. P. P., da Silva de Avó, L. R., & Bagnato, V. S. (2021). Tumor radiosensitization by photobiomodulation. Journal of Photochemistry and Photobiology. B, Biology, 225, 112349. https://doi.org/10.1016/j.jphotobiol.2021.112349
CAS Article PubMed Google Scholar
Finlayson, L., Barnard, I. R. M., McMillan, L., Ibbotson, S. H., Brown, C. T. A., Eadie, E., & Wood, K. (2022). Depth penetration of light into skin as a function of wavelength from 200 to 1000 nm. Photochemistry and Photobiology, 98(4), 974–981. https://doi.org/10.1111/php.13550
CAS Article PubMed Google Scholar
Samarasinghe, V., & Madan, V. (2012). Nonmelanoma skin cancer. Journal of Cutaneous and Aesthetic Surgery, 5(1), 3–10. https://doi.org/10.4103/0974-2077.94323
留言 (0)